{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:58:17Z","timestamp":1783641497814,"version":"3.55.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Allogeneic hematopoietic stem cell transplantation is the treatment of choice for high-risk hematological malignancies such as acute myeloid and lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Alternative donor transplantation from either haploidentical (haplo-SCT) or cord blood donor (CBT) is an established therapeutic alternative for patients who need transplants but lack a human leukocyte antigen\u2013matched donor. Although haplo-SCT (mainly non\u2013T-cell-depleted haplo-SCT with posttransplant cyclophosphamide) is increasing while CBT is decreasing worldwide (Figure 1), recent developments in CBT, especially cord blood expansion and other strategies to improve engraftment and immune reconstitution post-CBT, make CBT still a valuable option. This article discusses the 2 options based on the currently available data, focusing on adults, and tries to give some clues to help the transplant physician choose a haploidentical vs a cord blood donor. Given the limited numbers of published or ongoing well-designed randomized controlled trials comparing haplo-SCT to CBT and the overall similar clinical results in the available, mostly registry-based, and single-center studies, with substantial heterogeneity and variability, the decision to perform haplo-SCT or CBT in a given patient depends not only on the patient, disease, and donor characteristics and donor availability (although most if not all patients should have in principle an alternative donor) but also on the transplant physician's discretion and, most importantly, the center's experience and preference and ongoing protocols and strategies.<\/jats:p>","DOI":"10.1182\/hematology.2022000327","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:14:38Z","timestamp":1670602478000},"page":"64-73","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["In 2022, which is preferred: haploidentical or cord transplant?"],"prefix":"10.1182","volume":"2022","author":[{"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[{"name":"1 Division of Hematology, Bone Marrow Transplantation, and Hemato-Oncology Center, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel"},{"name":"2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"3 Acute Leukemia Working Party, European Society for Blood and Marrow Transplantation, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"3 Acute Leukemia Working Party, European Society for Blood and Marrow Transplantation, Paris, France"},{"name":"4 Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, Assistance Publique-H\u020fpitaux de Paris, Sorbonne University, Paris, France"},{"name":"5 Sorbonne University, INSERM, Saint-Antoine Research Center, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"21","key":"2023011318100159600_hem2022000327C1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.2019001323","article-title":"How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide","volume":"134","author":"McCurdy","year":"2019","journal-title":"Blood"},{"issue":"suppl 2","key":"2023011318100159600_hem2022000327C2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41409-019-0610-5","article-title":"Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia\u2014an update on behalf of the ALWP of the EBMT","volume":"54","author":"Nagler","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2023011318100159600_hem2022000327C3","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.bbmt.2020.07.030","article-title":"Guidelines for cord blood unit selection","volume":"26","author":"Politikos","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023011318100159600_hem2022000327C4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/17474086.2016.1128321","article-title":"Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications","volume":"9","author":"Baron","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"2023011318100159600_hem2022000327C5","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/bloodadvances.2019000200","article-title":"Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning","volume":"3","author":"van Besien","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2023011318100159600_hem2022000327C6","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2015.98","article-title":"Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia","volume":"29","author":"Ruggeri","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2023011318100159600_hem2022000327C7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/bloodadvances.2016002386","article-title":"Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1","volume":"1","author":"Versluis","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"2023011318100159600_hem2022000327C8","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023011318100159600_hem2022000327C9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-018-0655-8","article-title":"Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine","volume":"11","author":"Giannotti","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2023011318100159600_hem2022000327C10","doi-asserted-by":"crossref","first-page":"334.1","DOI":"10.1016\/j.jtct.2021.01.023","article-title":"Single cord blood transplantation versus unmanipulated haploidentical transplantation for adults with acute myeloid leukemia in complete remission","volume":"27","author":"Konuma","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2023011318100159600_hem2022000327C11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/TP.0000000000004006","article-title":"Single cord blood transplantation versus HLA-haploidentical-related donor transplantation using posttransplant cyclophosphamide in patients with hematological malignancies","volume":"106","author":"Wada","year":"2022","journal-title":"Transplantation"},{"issue":"20","key":"2023011318100159600_hem2022000327C12","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/bloodadvances.2021004462","article-title":"Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning","volume":"5","author":"Wagner","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2023011318100159600_hem2022000327C13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/bloodadvances.2021004916","article-title":"Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"6","author":"Wieduwilt","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2023011318100159600_hem2022000327C14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/bloodadvances.2020003369","article-title":"Low 5-year health care burden after umbilical cord blood transplantation","volume":"5","author":"Garcia","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2023011318100159600_hem2022000327C15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2023011318100159600_hem2022000327C16","doi-asserted-by":"crossref","first-page":"406.e1","DOI":"10.1016\/j.jtct.2022.03.024","article-title":"Impact of center experience with donor type on outcomes: a secondary analysis, Blood and Marrow Transplant Clinical Trials Network 1101","volume":"28","author":"Brunstein","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2023011318100159600_hem2022000327C17","doi-asserted-by":"crossref","first-page":"109.1","DOI":"10.1016\/j.jtct.2021.11.002","article-title":"Umbilical cord blood or HLA-haploidentical transplantation: real-world outcomes versus randomized trial outcomes","volume":"28","author":"O'Donnell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2023011318100159600_hem2022000327C18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2019.10.014","article-title":"Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-haploidentical related stem cell transplantation for adults with hematologic malignancies","volume":"26","author":"Sanz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023011318100159600_hem2022000327C19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clml.2021.09.024","article-title":"A comparison of the clinical outcomes of haploidentical transplantation and other graft sources in acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"22","author":"Owattanapanich","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2023011318100159600_hem2022000327C20","unstructured":"Li\n              D\n            , LiX, LiaoL, LiN. Unrelated cord blood transplantation versus haploidentical transplantation in adult and pediatric patients with hematological malignancies\u2014a meta-analysis and systematic review. Am J Blood Res. 2020;10(1):1-10. https:\/\/pubmed.ncbi.nlm.nih.gov\/32206440\/. Accessed 1February2020."},{"issue":"Jan-Dec","key":"2023011318100159600_hem2022000327C21","first-page":"963689720964771","article-title":"Haploidentical hematopoietic stem cell transplantation versus umbilical cord blood transplantation in hematologic malignancies: a systematic review and meta-analysis","volume":"29","author":"Wu","year":"2020","journal-title":"Cell Transplant"},{"issue":"5","key":"2023011318100159600_hem2022000327C22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2023011318100159600_hem2022000327C23","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2023011318100159600_hem2022000327C24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/ajh.25082","article-title":"T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"93","author":"Canaani","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"2023011318100159600_hem2022000327C25","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/leu.2017.42","article-title":"Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis","volume":"31","author":"Ustun","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"2023011318100159600_hem2022000327C26","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3324\/haematol.2020.264424","article-title":"Use of the HLA-B leader to optimize cord blood transplantation","volume":"106","author":"Petersdorf","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"2023011318100159600_hem2022000327C27","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","article-title":"Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2023011318100159600_hem2022000327C28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbmt.2018.08.026","article-title":"HLA-mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis","volume":"25","author":"Robin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2023011318100159600_hem2022000327C29","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41409-019-0582-5","article-title":"Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT","volume":"54","author":"Ruggeri","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2023011318100159600_hem2022000327C30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bjh.17406","article-title":"Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome","volume":"193","author":"Childs","year":"2021","journal-title":"Br J Haematol"},{"issue":"14","key":"2023011318100159600_hem2022000327C31","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.19.02408","article-title":"Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR","volume":"38","author":"Fatobene","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"2023011318100159600_hem2022000327C32","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41409-021-01426-3","article-title":"Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Therapie Cellulaire","volume":"56","author":"Cornillon","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2023011318100159600_hem2022000327C33","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/10428194.2013.802780","article-title":"Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review","volume":"55","author":"Messer","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023011318100159600_hem2022000327C34","doi-asserted-by":"crossref","first-page":"173.1","DOI":"10.1016\/j.jtct.2021.12.010","article-title":"Clinical outcomes of B cell acute lymphoblastic leukemia patients treated with haploidentical stem cells combined with umbilical cord blood transplantation","volume":"28","author":"Zhou","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2023011318100159600_hem2022000327C35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2017.10.040","article-title":"Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia","volume":"24","author":"Hsu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023011318100159600_hem2022000327C36","article-title":"Effects of different types of allogeneic hematopoietic stem cell transplantation donors on Philadelphia chromosome-positive acute lymphoblastic leukemia during the tyrosine kinase inhibitor era: a systematic review and meta-analysis [published online ahead of print 2 June 2022]","author":"Ponvilawan","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"6","key":"2023011318100159600_hem2022000327C37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s12519-021-00461-w","article-title":"Comparison of clinical outcomes between unrelated single umbilical cord blood and \u201cex-vivo\u201d T-cell depleted haploidentical transplantation in children with hematological malignancies","volume":"17","author":"G\u00f3mez-Santos","year":"2021","journal-title":"World J Pediatr"},{"issue":"9","key":"2023011318100159600_hem2022000327C38","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/ijc.30249","article-title":"Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia","volume":"139","author":"Mo","year":"2016","journal-title":"Int J Cancer"},{"issue":"16","key":"2023011318100159600_hem2022000327C39","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.2021011719","article-title":"Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2023011318100159600_hem2022000327C40","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/s41375-020-0733-0","article-title":"ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia","volume":"34","author":"Roy","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2023011318100159600_hem2022000327C41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/hon.2772","article-title":"Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide","volume":"38","author":"Sol\u00e1n","year":"2020","journal-title":"Hematol Oncol"},{"issue":"2","key":"2023011318100159600_hem2022000327C42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"JACC CardioOncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/64\/2026151\/64nagler.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/64\/2026151\/64nagler.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T18:10:36Z","timestamp":1673633436000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/64\/493552\/In-2022-which-is-preferred-haploidentical-or-cord"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000327","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}